Infinimmune

Executive Summary

Infinimmune is a private biotech company that discovers rare, naturally occurring antibodies from human donors and engineers them into therapeutic biologics. Founded in 2021 and headquartered in San Francisco, the company is currently in Phase 1 stage, focusing on advancing its lead candidates into the clinic. By systematically surfacing antibodies that evolution has already proven effective in humans, Infinimmune aims to develop safer and more effective treatments. The platform has the potential to generate multiple candidates across various indications, offering a differentiated approach in the antibody therapeutics space. However, given its early stage, the company faces risks related to clinical development, regulatory approval, and funding. The next major milestone is likely the submission of an Investigational New Drug (IND) application for its lead program. Securing strategic partnerships or additional financing will be critical for advancing its pipeline. Overall, Infinimmune represents a high-risk, high-reward opportunity in biologics.

Upcoming Catalysts (preview)

• Q3 2026FDA IND Acceptance for Lead Antibody Candidate70% success
• H2 2026Strategic Partnership with Large Pharma for Platform Access50% success
• 2026Series B Financing Round Completion80% success